Conventional approaches for estimating risks in disease mapping or mortality studies are based on Poisson inference. Frequently, overdispersion is present and this extra variability is modelled by introducing random effects. In this paper we compare two computationally simple approaches for incorporating random effects: one based on a non-parametric mixture model assuming that the population arises from a discrete mixture of Poisson distributions, and the second using a Poisson-normal mixture model which allows for spatial autocorrelation. The comparison is focused on how well each of these methods identify the regions which have high risks. Such identification is important because policy makers may wish to target regions associated with such extreme risks for financial assistance while epidemiologists may wish to target such regions for further study. The Poisson-normal mixture model is presented from both a frequentist, or empirical Bayes, and a fully Bayesian point of view. We compare results obtained with the parametric and non-parametric models specifically in terms of detecting extreme mortality risks, using infant mortality data of British Columbia, Canada, for the period 1981-1985, breast cancer data from Sardinia, for the period 1983-1987, and Scottish lip cancer data for 1975-1980. However, we also investigate the performance of these models in a simulation study. The key finding is that discrete mixture models seem to be able to locate regions which experience high risks; normal mixture models also work well in this regard, and perform substantially better when spatial autocorrelation is present.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/sim.821 | DOI Listing |
J Vis
January 2025
Institut de Neurosciences de la Timone, CNRS & Aix-Marseille Université, Marseille, France.
Sensory-motor systems can extract statistical regularities in dynamic uncertain environments, enabling quicker responses and anticipatory behavior for expected events. Anticipatory smooth pursuit eye movements (aSP) have been observed in primates when the temporal and kinematic properties of a forthcoming visual moving target are fully or partially predictable. To investigate the nature of the internal model of target kinematics underlying aSP, we tested the effect of varying the target kinematics and its predictability.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.
Background: Genome-wide association studies (GWAS) in Alzheimer's disease (AD) leveraging endophenotypes beyond case/control diagnosis, such as brain amyloid β pathology, have shown promise in identifying novel variants and understanding their potential functional impact. In this study, we leverage two brain amyloid β pathology measurement modalities, PET imaging and neuropathology, to address sample size limitations and to discover novel genetic drivers of disease.
Method: We conducted a meta-analysis on an amyloid PET imaging GWAS (N = 7,036, 35% amyloid positive, 53.
Alzheimers Dement
December 2024
Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Background: New methods developed to estimate when AD biomarkers became abnormal in individuals have shown considerable heterogeneity in amyloid and tau pathology onset age. This work used polygenic scores (PGS) generated from CSF Aβ and ptau GWAS, individual-level genetic data, and estimated tau onset age (ETOA) to identify genetic influences on tau onset beyond APOE.
Method: Participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with genetic data, CSF biomarkers (Aβ and ptau), and longitudinal [F]Flortaucipir (FTP) tau PET were analyzed (N = 462).
Alzheimers Dement
December 2024
Boston University School of Public Health, Boston, MA, USA.
Background: The Alzheimer's Disease Sequencing Project (ADSP) aims to identify genetic variation contributing to the development or protection of Alzheimer's disease (AD) in diverse ancestral populations. The latest ADSP whole genome sequencing (WGS) data release includes over 36,000 individuals from 37 datasets (NIAGADS NG00067.v11 ADSP R4).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of California San Diego, La Jolla, CA, USA.
Background: Our data from several clinical trials of individuals with asymptomatic AD demonstrates that plasma Aβ42/40 quantification by mass spectrometry can serve as a reliable biomarker for predicting elevated brain amyloid as detected by PET. We investigated how adding plasma p-tau measures to our plasma Aβ42/40 algorithm to streamline identification of eligible participants and reduce burden and trial cost. To determine if the addition of plasma p-tau181 and/or p-tau217 concentrations can improve plasma Aβ42/40 algorithms to correctly identify participants with amyloid burden of >20 centiloids with the NAV4694 tracer among individuals screening for participation in the AHEAD preclinical AD trial.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!